BA assessment of Spray vs topical powder [PK / PD]

posted by jag009  – NJ, 2022-04-11 20:24 (1123 d 15:08 ago) – Posting: # 22929
Views: 2,586

Thanks Dshah,

We are thinking of making a spray to replace a topical powder. Its a locally acting drug with the intent to treat a specific part of the body where the infection occurs. Yes a clinical endpt study is the obvious choice, not to mention that the systemic BA is less than 1%. I was wondering if one can get by without doing a clinical endpt study though, maybe a dermal study? For a dermal study, if the location of treatment is specific, does that mean the dermal study would have to involve the same area of the skin that the treatment is applied to as per reference product label?

Thx
J

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
127 visitors (0 registered, 127 guests [including 10 identified bots]).
Forum time: 11:32 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5